22q11.2 microdeletion and increased risk for type 2 diabetes

Area of Science:

• Genetics
• Endocrinology
• Metabolic Disorders

Background:

• 22q11.2 deletion syndrome (22q11.2DS) is a genetic disorder caused by a microdeletion on chromosome 22.
• Known endocrinological issues include hypoparathyroidism and hypothyroidism, with increased obesity risk in adults.
• The study investigates the link between 22q11.2DS and type 2 diabetes (T2D) risk.

Purpose of the Study:

• To determine if adults with 22q11.2DS have an elevated risk of developing T2D.
• To identify the 22q11.2 microdeletion as a potential risk factor for T2D.

Main Methods:

• Analysis of weighted survey data from the Canadian population (n=11,874) and a clinical cohort of adults with 22q11.2DS (n=314).
• T2D diagnosis based on medical history and glycosylated hemoglobin (HbA1c) levels.
• Binomial logistic regression models adjusted for age, sex, ethnicity, family history, obesity, and antipsychotic use.

Main Results:

• The 22q11.2 microdeletion is an independent risk factor for T2D (OR 2.44, p < 0.0001).
• Individuals with 22q11.2DS were diagnosed with T2D at a significantly younger median age (32 vs 50 years).
• Higher HbA1c levels were observed in adults with 22q11.2DS without T2D compared to the general population.

Conclusions:

• The 22q11.2 microdeletion is a novel independent risk factor for T2D, particularly early-onset T2D.
• Rare copy number variations (CNVs) may play a role in T2D risk.
• Findings support precision medicine approaches and further research into T2D pathogenesis.